Investment Thesis
Globus Medical demonstrates exceptional operational profitability with 96.7% gross margins, strong revenue growth of 16.7% YoY, and robust free cash flow of $162.7M. The company maintains a fortress balance sheet with zero debt, $561M in cash, and excellent liquidity (4.56x current ratio). However, extremely low ROE (2.6%) and ROA (2.3%) despite 16.4% net margins indicate capital efficiency concerns requiring monitoring.
Strengths
- Exceptional gross margin of 96.7% demonstrates strong pricing power and operational efficiency typical of medical device leaders
- Solid revenue growth of 16.7% YoY with healthy operating margin of 19.8% showing sustainable profitability
- Outstanding balance sheet with zero debt, $561M cash reserves, and current ratio of 4.56x providing significant financial flexibility
- Strong free cash flow generation of $162.7M (21.4% FCF margin) with operating cash flow significantly supporting reported earnings quality
Risks
- Disproportionate 422% YoY net income growth versus 16.7% revenue growth suggests one-time items or cost reductions that may not be sustainable
- Critical red flag: ROE of 2.6% and ROA of 2.3% are severely disconnected from 16.4% net margins, indicating poor capital allocation or asset utilization efficiency
- Limited insider activity (2 Form 4 filings in 90 days) provides minimal signal on management confidence or capital deployment intentions
Key Metrics to Watch
- Return on Equity trend - Must improve materially to justify capital base; current 2.6% suggests significant capital inefficiency
- Operating cash flow sustainability and conversion to earnings - Verify 422% net income growth drivers and margin expansion repeatability
- Capital expenditure trajectory and ROIC - Monitor whether $39.6M capex is sufficient for growth and how efficiently deployed capital generates returns
Financial Metrics
Revenue
759.9M
Net Income
124.3M
EPS (Diluted)
$0.90
Free Cash Flow
162.7M
Total Assets
5.4B
Cash
561.0M
Profitability Ratios
Gross Margin
96.7%
Operating Margin
19.8%
Net Margin
16.4%
ROE
2.6%
ROA
2.3%
FCF Margin
21.4%
Balance Sheet & Liquidity
Current Ratio
4.56x
Quick Ratio
2.95x
Debt/Equity
0.00x
Debt/Assets
13.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T10:51:36.643462 |
Data as of: 2026-03-31 |
Powered by Claude AI